ECONOMIC BURDEN OF ACUTE MYOCARDIAL INFARCTION (AMI) IN JAPAN AND THE ROLE OF CARDIOVASCULAR INFLAMMATION
Author(s)
Vasanth R. Krishnakumar, Other1, Takayuki Kifuji, MPH2, Ikki Komatsu, MD, PhD2, Marc Künkel Winther, MSc3, Ken Kozuma, MD, PhD4, Julie Thietje Mortensen, MSc, PhD5, Iram Muhammad, MD, PhD3, Tsunoda Yoshiaki, PhD2.
1Novo Nordisk GBS, Bengaluru, India, 2Novo Nordisk Pharma Ltd, Tokyo, Japan, 3Novo Nordisk A/S, Søborg, Denmark, 4Department of Cardiology, Teikyo University Hospital, Tokyo, Japan, 5Novo Nordisk, Søborg, Denmark.
1Novo Nordisk GBS, Bengaluru, India, 2Novo Nordisk Pharma Ltd, Tokyo, Japan, 3Novo Nordisk A/S, Søborg, Denmark, 4Department of Cardiology, Teikyo University Hospital, Tokyo, Japan, 5Novo Nordisk, Søborg, Denmark.
OBJECTIVES: To estimate healthcare resource utilization (HCRU), and direct healthcare costs among individuals with acute myocardial infarction (AMI) in Japan and evaluate the role of cardiovascular (CV) inflammation.
METHODS: An observational cohort study was conducted using the Japanese Medical Data Vision (MDV) hospital claims database. Eligible individuals were aged ≥40 years with a diagnosis of AMI between January 2017 and December 2025. Outcomes included per-patient-per-year (PPPY) direct healthcare costs and HCRU, captured as inpatient, outpatient, emergency room (ER), and prescription drug related visits. Costs were presented in EUR (¥1 = €0.0054). Age- and sex-standardized rates were calculated using direct standardization (2020 Japan Census). C-reactive protein (CRP) measurements 7-365 days prior to index date, defined as the initial AMI diagnosis date, were included and individuals were categorized into those with CV inflammation (defined as CRP ≥2 mg/L).
RESULTS: The cohort comprised 306,314 eligible individuals (mean age 72.9 ± 12.8 years; 68% male), of whom 8,742 individuals (3%) had baseline CRP measurements. Among the individuals with CRP measurements, 4,237 had CV inflammation. Crude and age- and sex-adjusted PPPY total all-cause direct healthcare costs were estimated at €3,860 and €3,691 respectively for individuals with AMI. Corresponding PPPY total HCRU was 8.665 and 8.823, respectively. Total yearly direct healthcare costs were higher among individuals with CV inflammation (Crude: €5,639, Adjusted: €5,825), and total yearly total visits were also higher (Crude: 16.924; Adjusted: 18.146).
CONCLUSIONS: AMI in Japan is associated with a substantial overall economic burden. Within this population, individuals with CV inflammation incurred higher direct healthcare costs. These findings highlight the importance of identifying individuals with CV inflammation and underscore the unmet treatment need in this population from a healthcare economic perspective.
METHODS: An observational cohort study was conducted using the Japanese Medical Data Vision (MDV) hospital claims database. Eligible individuals were aged ≥40 years with a diagnosis of AMI between January 2017 and December 2025. Outcomes included per-patient-per-year (PPPY) direct healthcare costs and HCRU, captured as inpatient, outpatient, emergency room (ER), and prescription drug related visits. Costs were presented in EUR (¥1 = €0.0054). Age- and sex-standardized rates were calculated using direct standardization (2020 Japan Census). C-reactive protein (CRP) measurements 7-365 days prior to index date, defined as the initial AMI diagnosis date, were included and individuals were categorized into those with CV inflammation (defined as CRP ≥2 mg/L).
RESULTS: The cohort comprised 306,314 eligible individuals (mean age 72.9 ± 12.8 years; 68% male), of whom 8,742 individuals (3%) had baseline CRP measurements. Among the individuals with CRP measurements, 4,237 had CV inflammation. Crude and age- and sex-adjusted PPPY total all-cause direct healthcare costs were estimated at €3,860 and €3,691 respectively for individuals with AMI. Corresponding PPPY total HCRU was 8.665 and 8.823, respectively. Total yearly direct healthcare costs were higher among individuals with CV inflammation (Crude: €5,639, Adjusted: €5,825), and total yearly total visits were also higher (Crude: 16.924; Adjusted: 18.146).
CONCLUSIONS: AMI in Japan is associated with a substantial overall economic burden. Within this population, individuals with CV inflammation incurred higher direct healthcare costs. These findings highlight the importance of identifying individuals with CV inflammation and underscore the unmet treatment need in this population from a healthcare economic perspective.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE321
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), No Additional Disease & Conditions/Specialized Treatment Areas